AC
FTH

Aaron Cowen’s Faeth Therapeutics FTH Stock Holding History

Aaron Cowen’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$50.5M Buy
2,020,103
+1,985,554
+5,747% +$45.9M 0.92% 31
2026
Q1 		$1.09M Buy
+34,549
New +$690K 0.03% 77

Other funds holding FTH

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Aaron Cowen's FTH Position: Q2 2026 in Review

Aaron Cowen increased its Faeth Therapeutics (FTH) stake by 5,747% in Q2 2026, buying an estimated $45.9M and bringing the position to 2,020,103 shares worth $50.5M. The position accounts for 0.92% of the portfolio, ranked #31.

Aaron Cowen first reported a position in FTH in Q1 2026 and has held it in 2 quarters since. 45 funds tracked by Wall St. Rank hold FTH as of Q2 2026.

  • Aaron Cowen held 2,020,103 shares of Faeth Therapeutics worth $50.5M as of Q2 2026.
  • Aaron Cowen bought 1,985,554 Faeth Therapeutics shares in Q2 2026, an estimated $45.9M.
  • Faeth Therapeutics made up 0.92% of Aaron Cowen's portfolio in Q2 2026, its #31 holding.
  • Aaron Cowen first reported a position in Faeth Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 45 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q2 2026.

Based on Suvretta Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.